Lipid and apolipoprotein patterns during erythropoietin therapy: Roles of erythropoietin, route of administration, and diet

Nephrology Dialysis Transplantation

Volumn 12, Issue 5, 1997, Pages 924-932

  Allegra, V ^a,b   Martimbianco, L ^a   Vasile, A ^a  

^a Ospedale di Palmanova   (Italy)

^b Regione Piemonte USL 49   (Italy)

Author keywords

Apolipoproteins; Cardiovascular risk; Erythropoietin; Haemodialysis; Lipid metabolism

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FOOD INTAKE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANEMIA; APOLIPOPROTEINS; DIET; EATING; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 0030989231     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.5.924     Document Type: Article

References (33)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
2. Escbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
3. Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 1989; 9 [suppl 1]: 30-34
4. Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; 1: 97-100
5. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991; 58: 129-134
6. Lundin AP, Akerman MJH, Chesler RM et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron 1991; 58: 315-319
7. Temple RM, Langan SJ, Deary IJ, Winney RJ. Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients. Nephrol Dial Transplant 1992; 7: 240-245
8. Nissenson AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989; 9 [suppl 2]: 25-31
9. Grimm PC, Sinai-Triema L, Sekiya NM et al. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990; 38: 12-18
10. Kokot F, Wiecek A, Marcinkowski W, Rudka R, Trembecki J. Suppression of the pituitary-adrenal axis and somatotropin (HGH) secretion is time-dependent in haemodialyzed patients (HDP) with chronic uraemia on long-term erythropoietin (Epo) therapy. Nephrol Dial Transplant 1992; 7: 768
11. Schaefer RM, Kokot F, Kuerner B, Zech M, Heiland A. Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. Int J Artif Organs 1989; 7: 445-449
12. Kokot F, Wiecek A, Grzeszczak W, Klepacka J, Klin M, Lao M. Influence of erythropoietin treatment on endocrine abnormalities in hemodialyzed patients. Contrib Nephrol 1989; 76: 257-272
13. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant 1993; 8: 93
14. Fischer CH, Scigalla P, Park W et al. Influence of rHuEpo therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency. Contrib Nephrol 1989; 76: 250-256
15. Riedel E, Hampl H, Scigalla P, Nundel M, Kessel M. Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients. Int Soc Nephrol 1989; 36(27): 216-221
16. Bucciante G, Piva M, Bortolazzi A, Bernardi AM. Esercizio fisico in pazienti in trattamento emodialitico: aspetti nutrizionali. In Saporiti E, Nordio M (eds) L'esercizio fisico nel dializzato. Wichtig, Milano 1991; 103-110, discussion 139
17. Mat O, Stolear JC, Georges B. Blood lipid profile in hemodialysis patients treated with human erythropoietin. Nephron 1992; 60: 236-237 (letter)
18. Prata MM, Sousa FT, Barbas JM. Rodrigues MC. Blood lipids in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 1990; 5: 474 (letter)
19. Viron B, Donsimoni R, Michel C, Al Khayat R, Mignon F. Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients. Nephron 1992; 60: 249 (letter)
20. Pollock CA, Wyndham R. Collet PV et al. Effects of erythropoietin on the lipid profile in end-stage renal failure. Kidney Int 1994; 45: 897-902
21. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-182
22. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28: 526-534
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
24. Wilson PWF, Zech LA, Gregg RE et al. Estimation of VLDL cholesterol in hyperlipemia. Clin Chim Acta 1985; 151: 285-291
25. Lentner C. Tavole scientifiche Geigy. Vicenza, Ciba-Geigy, vol. 3, 1985; 324-327
26. Low I, Grutzmacher P, Bergmann N, Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant erythropoietin. Clin Nephrol 1989; 31: 36-40
27. Canella G, La Canna G, Sandrini M et al. Renormalization of high cardiac output and of left ventricular size following long term recombinant human erythropoietin treatment of anaemic dialysed patients. Clin Nephrol 1990; 34: 272-278
28. Nepokroeff CM, Lakshmanan MR, Ness GC, Dugan RE, Porter JW. Regulation of the diurnal rhythm of rat liver hydroxymethylglutaryl coenzime A reductase activity by insulin, glucagon, cyclic AMP and hydrocortisone. Arch Biochem Biophys 1974; 160: 387-393
29. Blumenkrantz MI, Kopple JD, Gutman RA et al. Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr 1980; 33: 1567-1587
30. Canaud B, Bouloux C, Rivory JP et al. Erythropoietin-induced changes in protein nutrition: quantitative assessment by urea kinetic modeling analysis. Blood Purif 1990; 8: 301-308
31. Barany P, Pettersson E, Ahlberg M et al. Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 1991; 35: 270-279
32. Lavie CJ, Gay GT, Squires RW, Rottke BA. Management of lipids in primary and secondary prevention of vascular diseases. Mayo Clin Proc 1988; 63: 605-621
33. Caravaca F, Pizarro JL, Arrobas M, Cubero JJ, Garcia MC, Perez-Miranda M. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994; 45: 845-851